The synergy between technology and sales force

The Avastin market increased by 36% in the first half of the year

Samsung Onbevzi's quarterly sales exceeded 10 billion won in two years

Sales surged due to the increase of 'anticancer drug powerhouse

Domestically developed biosimilar products are prominent in the large anticancer drug Asastin market.

 

Samsungbioepis' Onbevzi exceeded 10 billion won in quarterly sales in the first two years of its release, showing a 35% share.

 

It is said that Boryung, which was the first biosimilar to enter the market and has differentiated strengths in anticancer drug sales, added to sales and maximized synergy.

 

According to IQVIA, a pharmaceutical research institute on the 29th, the market size of Bevacizumab in the first half of last year was 59.9 billion won, up 36.1% from the same period last year.

 

Sales in the first quarter were 29.5 billion won, up 39.8% from the previous year, and continued to grow at 30.4 billion won in the second quarter, a high growth rate of 32.8%.

 

Bevacizumab is the original medicine of Roche's Avastin.

 

It is an anticancer drug used for metamorphic direct colorectal cancer and metamorphic breast cancer, non-small cell lung cancer, advanced or metamorphic renal cell carcinoma, glioblastoma, epithelial ovarian cancer, topetic tube cancer, primary peritoneal cancer, and cervical cancer.

 

Domestically developed biosimilars recently led the expansion of the Bevacizumab market.

 

In the Avastin market, Samsung Bioepis released the Biosimilar in September 2021, with an additional entry from Celltrion and Alvogen Korea.

 

Onbevzi's sales in the first half of the year were 20.3 billion won, up 246.9% from the previous year.

 

Onbevzi's sales in the first quarter were 9.8 billion won, more than five times from 1.8 billion won in the same period last year, and recorded 10.5 billion won in the second quarter, up 157.0% from the previous year.

 

OnBev is the first time that a biosimilar product released by Samsung Bioepis has exceeded 10 billion won in quarterly sales.

 

Celltrion and Alvogen Korea, which entered the market this year, have quarterly sales of 100 to 200 million won.

 

Onbevzi was the first to enter the market among biosimilar products and maximized the synergy by equipping it with a customized sales force.

 

Samsung Bioepis signed a domestic exclusive sales contract with Boryeong shortly after OnBevji's domestic license.

 

Boryeong is one of the domestic companies that has strengths in the area of anticancer drugs.

 

Boryung established the anti-cancer division in May 2020.

 

The organization, which was under the specialty medicine sector, was independent as a separate division.

 

We have secured the rights to various anticancer drugs and biosimilars owned by domestic and foreign companies, and equipped with gems and notifications as a LBA strategy that buys the rights to the original anticancer drugs.

 

Boryung also secured domestic rights for Samsung Bioepis' Avastin and Herceptin biosimilar products in 2021.

 

Boryung is on the rise in the anticancer drug business in the first half of this year alone, with anticancer drug sales of 106.1 billion won, up 48% from the previous year.

 

From Boryung's point of view, it is also enjoying the effect of improving performance while equipping high-market products.

 

Samsung Bioepis Samphenet's sales in the first half of the year were 4.1 billion won, up 65.1% from the previous year.

 

Although the sales volume is not large, the effect of Boryeong's sales force was noticeable.

 

Sales of the original drug Avastin have not changed much.

 

In the first half of last year, Asastin's sales were 38.9 billion won, up 2.9% from the previous year.

 

Asastin's first- and second-quarter sales rose 0.4% and 3.6% year-on-year, respectively.

 

Avastin showed a stable growth flow of 28.7 billion won, 30.2 billion won and 30.8 billion won from the first quarter to the third quarter of 2021, but it was 22 billion won in the fourth quarter, down 28.6% from the previous quarter.

 

A decline in sales was inevitable due to the weakening of drug prices following the emergence of biosimilars.

 

Samsung Bioepis was approved for Avastin's first biosimilar OnBevji in March 2021 and has been listed on the health insurance benefit list since September of the same year.

 

In October 2021, the upper limit of 0.1g/4mL of Avastin was reduced by 30% from 33,387 won to 231,271 won due to the listing of OnBevji.

 

Avastin 0.4g/16mL fell 30%.

 

In principle, when biosimilars appear in the domestic drug price system, the upper limit of original medicines is 30% lower than before the patent expired.

 

'Innovative pharmaceutical companies, equivalent companies, domestic pharmaceutical companies, and foreign companies that have signed a joint contract, or items that Korea is the first licensed country or products produced in Korea' are guaranteed up to 80% of the original products before the patent expiration of both the original pharmaceuticals and biosimilars.

 

Because Samsung Bioepis is not an innovative pharmaceutical company, the price of Avastin's drug has fallen to the previous 70% level.

 

Avastin has experienced a decline in sales of the drug price reduction rate but has since formed similar-scale sales, minimizing the sales gap due to biosimilar penetration.

 

Onbevji had a 34.5% share of the Bevacizumab market in the second quarter.

 

Considering that there has been no additional drop in sales since the price drop by Asastin, Onbebge has actually created a new market worth 10 billion won in quarterly sales.

 

As a result, it is analyzed that the drug price of the original drug also fell by 30% due to the entry of Onbevji, resulting in a significant effect on health insurance finances and the reduction of drug prices for patients.